These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36607148)

  • 21. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
    Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.
    Geng C; Yang G; Wang H; Zhang Z; Zhou H; Chen W
    Biomed Res Int; 2021; 2021():6689457. PubMed ID: 34104651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.
    Geng C; Yang G; Wang H; Wu Y; Leng Y; Zhou H; Zhang Z; Jian Y; Chen W
    Leuk Lymphoma; 2021 Apr; 62(4):883-890. PubMed ID: 33275060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cytogenetic abnormalities and prognosis of 532 patients with multiple myeloma].
    Wu H; Zhang H; He HY; Jiang H; Zhao YY; An R; He J; Li R; Lu J; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):739-743. PubMed ID: 29081188
    [No Abstract]   [Full Text] [Related]  

  • 25. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
    Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
    Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
    Nahi H; Våtsveen TK; Lund J; Heeg BM; Preiss B; Alici E; Møller MB; Wader KF; Møller HE; Grøseth LA; Østergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
    Eur J Haematol; 2016 Jan; 96(1):46-54. PubMed ID: 25779478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
    Schavgoulidze A; Talbot A; Perrot A; Cazaubiel T; Leleu X; Manier S; Buisson L; Mahéo S; Do Souto Ferreira L; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Avet-Loiseau H; Corre J
    Blood; 2023 Mar; 141(11):1308-1315. PubMed ID: 36375118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?
    Gao L; Liu Y; Li Y; Feng L; Wang Z; Wen L; Wang F; Huang X; Lu J; Lai Y
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):535-544. PubMed ID: 35292207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
    Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
    Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
    [No Abstract]   [Full Text] [Related]  

  • 31. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.
    Jiang N; Qi C; Trieu Y; Reece D; Chang H
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1790-5. PubMed ID: 21658460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents.
    Sato S; Kamata W; Okada S; Tamai Y
    Int J Hematol; 2021 Feb; 113(2):207-213. PubMed ID: 32949373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China.
    Mei J; Zhai Y; Li H; Li F; Zhou X; Song P; Zhao Q; Yu Y; An Z; Wang L
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2263-2273. PubMed ID: 30167888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides.
    Xu J; Xu T; Yang Y; Wang W; Li J; Ren Y; Gu S; Chen C; Wei Z; Zhuang J; Wang Z; Ji L; Cheng L; Wang W; Cheng Z; Ke Y; Yuan L; Liu P
    Leuk Lymphoma; 2020 Oct; 61(10):2351-2364. PubMed ID: 32519901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The prognostic relationship between CD56 expression and newly diagnosed multiple myeloma].
    Geng CY; Yang GZ; Wang HJ; Zhou HX; Zhang ZY; Jian Y; Chen WM
    Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):164-171. PubMed ID: 35090251
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical characteristics of patients with multiple myeloma harboring 6q deletion].
    Chen L; Sun CY; An BW; Yu JM; Zhao F; Zhang C; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):642-645. PubMed ID: 34547869
    [No Abstract]   [Full Text] [Related]  

  • 37. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
    Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
    Gao S; Dong F; Yang P; Chen Y; Wang Y; Wang J; Shi Y; Jing H
    Ann Hematol; 2024 Jun; 103(6):1979-1987. PubMed ID: 38206369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
    Shah V; Sherborne AL; Walker BA; Johnson DC; Boyle EM; Ellis S; Begum DB; Proszek PZ; Jones JR; Pawlyn C; Savola S; Jenner MW; Drayson MT; Owen RG; Houlston RS; Cairns DA; Gregory WM; Cook G; Davies FE; Jackson GH; Morgan GJ; Kaiser MF
    Leukemia; 2018 Jan; 32(1):102-110. PubMed ID: 28584253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.